比较分析左西孟旦与米力农治疗老年顽固性心力衰竭临床疗效
|
摘要
目的比较顽固性心力衰竭(顽固性心衰)老年患者分别施予米力农、左西孟旦进行治疗的疗效。方法 80例研究对象均为方便选取该院心内科收治的顽固性心衰老年患者,纳入时间为2017年7月—2018年7月,将其中单纯实施米力农治疗的40例为A组,另外施予左西孟旦治疗的40例为B组,对比其疗效。结果 B组治疗后的LVEF、SV与BNP、QOL评分以及6MWT均优于A组,且B组治疗的总有效率是87.50%,较A组的67.50%高,B组再次住院率为12.50%,较A组的35.00%低,差异有统计学意义(P<0.05)。结论与米力农相比较,左西孟旦治疗顽固性心衰的疗效更为显著,价值更高。
Objective To compare the efficacy of milrinone and levosimendan in the treatment of refractory heart failure(refractory heart failure) in elderly patients. Methods 80 patients were convenient selected and enrolled in the elderly with refractory heart failure admitted to our hospital. The time of enrollment was from July 2017 to July 2018. 40 patients who underwent milrinone treatment alone were included in group A. 40 patients who were treated with levosimendan were given group B and their effects were compared. Results The LVEF, SV and BNP, QOL scores and 6 MWT were better in group B than in group A, and the total effective rate in group B was 87.50%, which was higher than 67.50% in group A. The rate of re-hospitalization in group B was 12.50%, which was lower than the 35.00% of the A group, and there was a statistical difference(P<0.05). Conclusion Compared with milrinone, levosimendan is more effective in treating refractory heart failure and has higher value.
Objective To compare the efficacy of milrinone and levosimendan in the treatment of refractory heart failure(refractory heart failure) in elderly patients. Methods 80 patients were convenient selected and enrolled in the elderly with refractory heart failure admitted to our hospital. The time of enrollment was from July 2017 to July 2018. 40 patients who underwent milrinone treatment alone were included in group A. 40 patients who were treated with levosimendan were given group B and their effects were compared. Results The LVEF, SV and BNP, QOL scores and 6 MWT were better in group B than in group A, and the total effective rate in group B was 87.50%, which was higher than 67.50% in group A. The rate of re-hospitalization in group B was 12.50%, which was lower than the 35.00% of the A group, and there was a statistical difference(P<0.05). Conclusion Compared with milrinone, levosimendan is more effective in treating refractory heart failure and has higher value.
引文
[1]张文佳,沃金善.左西孟旦与米力农治疗老年难治性心力衰竭临床疗效比较[J].临床合理用药杂志,2018,11(13):14-16.
[2]Tsuchida Keiichi,Fujihara Yuki,Hiroki Jiro,et al.Significance of Sarcopenia Evaluation in Acute Decompensated Heart Failure.[J].International heart journal,2018,59(1):143-148.
[3]Bredy Charlene,Ministeri Margherita,Kempny Alexander,,et al.New York Heart Association(NYHA)classification in adults with congenital heart disease:relation to objective measures of exercise and outcome.[J].European heart journal.Quality of care&clinical outcomes,2018,4(1):51-58.
[4]曾光豪,金杰,彭沪.不同剂量左西孟旦对慢性心力衰竭患者影响的对比研究[J].实用心脑肺血管病杂志,2017,25(7)62-65.
[5]林琳,唐农,刘布谷,等.小剂量多巴胺联合米力农对顽固性心力衰竭的疗效及对心功能的影响[J].现代生物医学进展,2017,17(33):6498-6501,6522.
[6]高鹏,寇广亚,武延海.左西孟旦治疗老年顽固性充血性心力衰竭并肾功能不全的疗效评价[J].实用医学杂志,201632(12):2041-2045.
[7]黄金剑,郭水连,刘艳丽,等.左西孟旦与米力农治疗顽固性心力衰竭合并呼吸衰竭患者疗效比较[J].山东医药,201656(5):62-63.
[8]胡学松,冷利华.左西孟旦与米力农注射液治疗老年失代偿性心力衰竭临床疗效的对比研究[J].实用心脑肺血管病杂志,2017,25(8):78-81.
[9]邹玉刚,杨茂勇,王婷婷,等.左西孟旦与米力农治疗失代偿性心力衰竭的近期疗效及预后比较[J].心血管康复医学杂志,2018,27(2):188-191.
[10]李兆雷,石伟林.米力农对老年顽固性心力衰竭患者血流动力学的影响[J].海峡药学,2018,30(9):182-183.
[11]郁秀芹.米力农联合生脉注射液治疗慢性心力衰竭临床疗效观察分析[J].中国现代药物应用,2018,12(10):82-83.
[12]卞静,宋涛,赵严,等.新活素联合左西孟旦治疗难治性心衰的临床研究[J].当代医学,2018,24(3):50-53.
[2]Tsuchida Keiichi,Fujihara Yuki,Hiroki Jiro,et al.Significance of Sarcopenia Evaluation in Acute Decompensated Heart Failure.[J].International heart journal,2018,59(1):143-148.
[3]Bredy Charlene,Ministeri Margherita,Kempny Alexander,,et al.New York Heart Association(NYHA)classification in adults with congenital heart disease:relation to objective measures of exercise and outcome.[J].European heart journal.Quality of care&clinical outcomes,2018,4(1):51-58.
[4]曾光豪,金杰,彭沪.不同剂量左西孟旦对慢性心力衰竭患者影响的对比研究[J].实用心脑肺血管病杂志,2017,25(7)62-65.
[5]林琳,唐农,刘布谷,等.小剂量多巴胺联合米力农对顽固性心力衰竭的疗效及对心功能的影响[J].现代生物医学进展,2017,17(33):6498-6501,6522.
[6]高鹏,寇广亚,武延海.左西孟旦治疗老年顽固性充血性心力衰竭并肾功能不全的疗效评价[J].实用医学杂志,201632(12):2041-2045.
[7]黄金剑,郭水连,刘艳丽,等.左西孟旦与米力农治疗顽固性心力衰竭合并呼吸衰竭患者疗效比较[J].山东医药,201656(5):62-63.
[8]胡学松,冷利华.左西孟旦与米力农注射液治疗老年失代偿性心力衰竭临床疗效的对比研究[J].实用心脑肺血管病杂志,2017,25(8):78-81.
[9]邹玉刚,杨茂勇,王婷婷,等.左西孟旦与米力农治疗失代偿性心力衰竭的近期疗效及预后比较[J].心血管康复医学杂志,2018,27(2):188-191.
[10]李兆雷,石伟林.米力农对老年顽固性心力衰竭患者血流动力学的影响[J].海峡药学,2018,30(9):182-183.
[11]郁秀芹.米力农联合生脉注射液治疗慢性心力衰竭临床疗效观察分析[J].中国现代药物应用,2018,12(10):82-83.
[12]卞静,宋涛,赵严,等.新活素联合左西孟旦治疗难治性心衰的临床研究[J].当代医学,2018,24(3):50-53.